New treatment options have helped increase survival rates for metastatic breast cancer. The stage at which cancer is diagnosed greatly affects the survival rate. There are factors like age and overall ...

A CD276-targeted antibody-drug conjugate combined with mitochondrial-disrupting gene therapy outperformed either treatment ...

Five-year overall survival (OS) for patients with de novo metastatic cancer increased from 10.6% in 1976-1981 to 23.6% in 2015-2020, representing more than a twofold improvement. Survival gains were ...

Treating individual metastatic tumors with highly focused radiation or surgery did not improve progression-free or overall ...

A retrospective study of 103 patients with HER2-positive de novo metastatic breast cancer found that those who underwent ...

Research findings from Flatiron Health and the Community Oncology Alliance show substantial growth in advanced ...

People who are marginalized or lack access to a primary care provider are at greater risk of early death from newly diagnosed ...

When Karis Quinn reflects on her mother, she remembers someone who refused to let cancer define her family's life.

Cindy Massari had already been treated for stage 1 breast cancer years before she got the difficult diagnosis — but she just ...